What is Heliogen's revenue?
As of July 2026, Heliogen’s trailing twelve-month (TTM) revenue is reported at approximately ₹1.75 billion. This figure reflects the company's financial performance within its market segment as it continues to develop its solar technology and energy solutions. Investors and analysts monitor this metric to assess the scale of the company’s commercial deployment and the growth of its revenue streams in the renewable energy sector.
Related FAQs
Elon Musk's most prominent new stock is the recently listed SpaceX, which trades under the ticker symbol SPCX. Following its June 2026 IPO, it became a major fixture on the NASDAQ exchange.
Heliogen, Inc. trades under the ticker symbol HLGN at a live market price of approximately $1.70 per share.
Market analysts covering AxoGen generally evaluate the medical technology stock with a balanced perspective, often leaning toward a cautious buy or hold rating.
Heliogen, Inc.
Heliogen, Inc. is a renewable energy technology enterprise that specializes in developing advanced concentrated solar power systems designed to decarbonize heavy industrial manufacturing.
Heliogen, Inc. trades on the New York Stock Exchange under the official stock ticker symbol HLGN.
Axogen, Inc. (traded on the Nasdaq under the ticker symbol AXGN) is a medical technology enterprise dedicated to the development and commercialization of proprietary surgical solutions for peripheral nerve repair and regeneration.
Space Exploration Technologies Corp., widely known as SpaceX, operates entirely as a privately held aerospace manufacturer and satellite communication enterprise founded by Elon Musk.
AxoGen has historically operated as a growth-stage medical device company focused heavily on scaling its commercial infrastructure, clinical education programs, and product manufacturing capacity, which has often resulted in net losses.